Emvision Medical Devices Ltd. · ASX:EMV
Emvision Medical Devices — Shareholder Meeting (November 2024)
17 slides from Emvision Medical Devices's shareholder meeting presentation, Nov 14, 2024
Slide 1: AGM Chair's Address & Managing Director Presentation
14/11/2024 EMVision Medical Devices Ltd ACN 620 388 230 Suite 4.01, 65 Epping Rd Sydney NSW 2113 02 8667 5337 contact@emvision.com.au AGM CHAIR’S ADDRESS & MANAGING DIRECTOR PRESENTATION EMVision Medical Devices Limited (ASX:EMV) (“EMVision” or the “Company”) is pleased to provide copies of the Chai
Slide 2: Chair's Address (continued)
Based on initial bench testing to date, we expect its performance capabilities to be at least equivalent, if not superior, to our emu™ device. It represents a genuine step change, that has the potential to alter the landscape of pre-hospital care, particularly as we see treatments move into the fiel
Slide 3: Forward-looking Statements
Forward-looking Statements This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These f
Slide 4: CEO Presentation AGM 2024
emvision.com.au For personal use only CEO PRESENTATION AGM 2024 First Responder Bedside Scanner Pre-hospital scanner
Slide 5: Disclaimer
DISCLAIMER This presentation has been prepared by EMVision Medical Devices Limited (“EMVision” or “the Company”). This presentation is not a financial product or For personal use only investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securiti
Slide 6: Overview
OVERVIEW EMVision (ASX:EMV) is an innovative medical device company developing and commercialising world first portable brain scanner products to address significant unmet clinical For personal use only needs. Founded in 2017 Significant non-dilutive after 10 years of R&D at federal and state grant
Slide 7: Meet the Team
MEET THE TEAM Significant medical device development and global commercialisation expertise across the group Executive Leadership Team Board of Directors For personal use only Scott Kirkland As former CEO of Queensland Diagnostic Imaging, Sales and marketing executive, former Head of John Keep CEO,
Slide 8: 2024 Highlights
2024 HIGHLIGHTS Exceptional neurodiagnostic Positive FDA engagement For personal use only performance demonstrated FDA meeting reinforced confidence that The EMView study provided very EMVision’s strategic direction is encouraging real-world evaluation of appropriate aligned with FDA diagnostic algo
Slide 9: Our vision is to reduce the global burden of stroke and other time sensitive medical emergencies
OUR VISION IS TO REDUCE THE GLOBAL BURDEN OF STROKE AND OTHER TIME SENSITIVE MEDICAL EMERGENCIES First indication Second indication For personal use only Stroke Traumatic brain injury (TBI) Types of Stroke • 1 in 4 adults will suffer from a stroke in their • 50 to 60 million people worldwide will li
Slide 10: CT scanners are vital in stroke care, but not readily available at the point-of-care
CT SCANNERS ARE VITAL IN STROKE CARE, BUT ARE NOT READILY AVAILABLE AT THE POINT-OF-CARE CT scanners cannot be widely deployed at the bedside, or in remote locations, or in every ambulance. EMVision’s products can address this unmet need. For personal use only Mobile Stroke Units (MSUs) are custom-b
Slide 11: Market Opportunity
MARKET OPPORTUNITY Attractive Revenue Models Total Addressable Market Traditional CapEx or innovative OpEx selling model For personal use only ADDRESSABLE MARKET ~$15B offerings to provide buyer flexibility through direct or distributor sales channels. US GER, FRA, UK AUS ROW Capital equipment and M
Slide 12: EMView Pre-Validation Clinical Trial Results
EMView PRE-VALIDATION CLINICAL TRIAL RESULTS The EMView multi-site study involved 307 participants, including 277 acute suspected stroke patients, enrolled at Liverpool Hospital, Royal Melbourne Hospital, and Princess Alexandra Hospital. Reading learning curves ‘Haemorrhage (bleed) or not’ For perso
Slide 13: EMView Pre-Validation Clinical Trial Results: Case Studies
EMView PRE-VALIDATION CLINICAL TRIAL RESULTS Exemplar case studies Probabilistic anatomical imaging case studies Very small haemorrhages successfully detected and classified EMVision Reconstruction Ground truth Base Advanced For personal use only Case #1 L R Right convexity subarachnoid haemorrhage
Slide 14: Our Path to Market Entry
and First Responder OUR PATH TO MARKET ENTRY We are here For personal use only Pre-Validation Trial Validation Trial (Pivotal) Regulatory Submission + Market Entry COMPLETED CY Q3 2024 TARGET COMMENCEMENT CY Q1 2025 LATE 2025+ ONWARDS Liverpool Hospital, Royal Melbourne Hospital, 6 sites FDA De Novo
Slide 15: Strategy for Continuous Innovation During Trials
STRATEGY FOR CONTINUOUS INNOVATION DURING TRIALS Validation Trials Pivotal For personal use only Target commencement CY Q1 2025 Up to 300 suspected stroke patients (indicative) Australian Sites American Sites V1 Software Validation Validation trials are conducted to demonstrate efficacy and Site #1
Slide 16: First Responder Domestic Feasibility Study Overview
First Responder DOMESTIC FEASIBILITY STUDY OVERVIEW Targeted commencement CY Q1 2025 Study design Prospective, Convenience Sample, Usability, Pilot Study For personal use only Investigational sites Road Ambulance Service Air Ambulance Service (Royal Flying Doctor Service) Estimated duration ≤ 6 mont
Slide 17: Set Up for Success
SET UP FOR SUCCESS ✓ We have assembled a team of MedTech experts that have KEY 2025 CATALYSTS successfully done this before and created significant shareholder value For personal use only Validation (pivotal) trial ✓ We have compelling support from the leading minds in activation, recruitment neurol
EMVision Medical Devices — Shareholder Meeting (November 2024) on 6ix